Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$18.42

0.01 (0.05%)

07:24
10/23/19
10/23
07:24
10/23/19
07:24

Alkermes sees 2019 Vivitrol sales $330M-$340M vs. prior outlook $330M-$350M

Alkermes lowered its 2019 Aristada sales outlook to $185M-$190M from $200M-$210M.

  • 23

    Oct

  • 06

    Nov

ALKS Alkermes
$18.42

0.01 (0.05%)

07/30/19
HCWC
07/30/19
NO CHANGE
Target $28
HCWC
Neutral
Alkermes settlement close to best-case scenario, says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao says Alkermes' (ALKS) settlement and license agreement with Amneal Pharmaceuticals (AMRX) provides a "measure of needed visibility." There was some investor nervousness coming into the hearing and this settlement "represents close to a best-case scenario for Alkermes," Tsao tells investors in a research note. Vivitrol's growth has slowed but 12% volume growth in Q2 indicates the franchise can continue to be a contributor for the foreseeable future, adds the analyst. Tsao thinks the bull thesis for Alkermes hinges largely on the prospects for ALKS-4230. The update that patients on ALKS-4230 appear to avoid capillary leak syndrome, which has limited the utility of IL-2 therapies in the past, is important, according to Tsao. He keeps a Neutral rating on Alkermes with a $28 price target.
07/30/19
JPMS
07/30/19
NO CHANGE
JPMS
Overweight
Alkermes, Biogen data a positive, but questions remain, says JPMorgan
JPMorgan analyst Cory Kasimov views the data this morning from Alkermes (ALKS) and Biogen (BIIB) as an incremental positive but he believes commercial questions remain for Vumerity. The analyst has an Overweight rating on Alkermes and Neutral rating on Biogen. How doctors will view this dataset and how aggressive Biogen will be in launching Vumerity in the face of questions regarding Tecfidera's ultimate runway are the next key questions, Kasimov tells investors in a research note. However, he calls this morning's news a "good-to-see outcome."
07/30/19
PIPR
07/30/19
NO CHANGE
PIPR
Neutral
Piper says Alkermes scores 'back-to-back wins' with settlement, Biogen data
Piper Jaffray analyst Danielle Brill said Alkermes (ALKS) has scored "back-to-back wins" with its announcement yesterday that it settled the ongoing Vivitrol patent dispute with Amneal (AMRX) and the news this morning that BIIB098 showed a statistically significant improvement on GI tolerability versus Tecfidera in a head-to-head Phase 3 trial. She still questions how meaningful the improvement in GI tolerability actually is, but thinks the drug may become a priority for partner Biogen (BIIB), Brill tells investors. The analyst, who views the news of the last two days as net positive for Alkermes, maintains her concerns about long-term value creation and the company's "dry pipeline," she said. Brill keeps a Neutral rating on Alkermes shares.
09/05/19
MSCO
09/05/19
UPGRADE
Target $20
MSCO
Equal Weight
Alkermes upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst David Risinger upgraded Alkermes to Equal Weight from Underweight while lowering his price target for the shares to $20 from $30. The stock has underperformed, and recent developments eliminated the worst-case scenarios for Vumerity trial results and Vivitrol's patent, Risinger tells investors in a research note. Although cancer pipeline candidate ALKS 4230 could still disappoint, consensus expectations are low due to a questionable profile, adds the analyst. He believes Alkermes' long-term risk to royalty streams is balanced by its pipeline or cost savings optionality at current share levels.

TODAY'S FREE FLY STORIES

EPAM

Epam Systems

$200.74

0.85 (0.43%)

06:09
11/14/19
11/14
06:09
11/14/19
06:09
Initiation
Epam Systems initiated  »

Epam Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

FENG

Phoenix New Media

$3.04

0.04 (1.33%)

06:07
11/14/19
11/14
06:07
11/14/19
06:07
Hot Stocks
Phoenix New Media declares 17.14c per share special cash dividend »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHX

Athersys

$1.37

0.04 (3.01%)

06:07
11/14/19
11/14
06:07
11/14/19
06:07
Hot Stocks
Athersys: Healios receives orphan designation for ARDS clinical program »

Athersys announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$48.44

0.06 (0.12%)

06:06
11/14/19
11/14
06:06
11/14/19
06:06
Recommendations
Cisco analyst commentary  »

Piper stays on sidelines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

GRUB

GrubHub

$36.63

-0.7 (-1.88%)

06:05
11/14/19
11/14
06:05
11/14/19
06:05
Periodicals
GrubHub to create 'task force' after NYC Council threatens action, NYP says »

GrubHub will create a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTT

Wireless Telecom Group Inc

$1.50

0.04 (2.74%)

06:05
11/14/19
11/14
06:05
11/14/19
06:05
Hot Stocks
Wireless Telecom Group Inc to Acquire Holzworth Instrumentation »

Wireless Telecom Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

FVRR

Fiverr

$22.55

0.99 (4.59%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Upgrade
Fiverr rating change  »

Fiverr upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

ROLL

RBC Bearings

$165.06

-1.19 (-0.72%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Downgrade
RBC Bearings rating change  »

RBC Bearings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$155.38

-2.295 (-1.46%)

06:04
11/14/19
11/14
06:04
11/14/19
06:04
Upgrade
Stanley Black & Decker rating change  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

NRZ

New Residential

$16.06

-0.07 (-0.43%)

06:03
11/14/19
11/14
06:03
11/14/19
06:03
Downgrade
New Residential rating change  »

New Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBEV

New Age Beverages

$2.50

0.04 (1.63%)

06:02
11/14/19
11/14
06:02
11/14/19
06:02
Earnings
New Age Beverages reports Q3 EPS (14c), consensus (4c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

06:02
11/14/19
11/14
06:02
11/14/19
06:02
Periodicals
SoftBank's Yahoo Japan in talks to merge with Naver's Line, Nikkei reports »

SoftBank's Yahoo…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$48.44

0.06 (0.12%)

06:01
11/14/19
11/14
06:01
11/14/19
06:01
Recommendations
Cisco analyst commentary  »

Citi keeps Buy on Cisco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

XRX

Xerox

$37.60

0.14 (0.37%)

, HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

06:00
11/14/19
11/14
06:00
11/14/19
06:00
Periodicals
Carl Icahn pushes for Xerox, HP Inc union, WSJ reports »

Carl Icahn, who owns a…

XRX

Xerox

$37.60

0.14 (0.37%)

HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

MYO

Myomo

$0.54

-0.1126 (-17.26%)

05:58
11/14/19
11/14
05:58
11/14/19
05:58
Downgrade
Myomo rating change  »

Roth Capital downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLGT

Fulgent Genetics

$13.62

0.11 (0.81%)

05:57
11/14/19
11/14
05:57
11/14/19
05:57
Syndicate
Fulgent Genetics 2.325M share Spot Secondary priced at $11.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

ECOR

electroCore

$1.88

0.06 (3.30%)

05:56
11/14/19
11/14
05:56
11/14/19
05:56
Downgrade
electroCore rating change  »

electroCore downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOR

electroCore

05:56
11/14/19
11/14
05:56
11/14/19
05:56
Downgrade
electroCore rating change  »

electroCore downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:55
11/14/19
11/14
05:55
11/14/19
05:55
Conference/Events
SunTrust hosted company meetings at conference »

SunTrust hosted Meetings…

NICE

Nice

$159.16

0.87 (0.55%)

05:54
11/14/19
11/14
05:54
11/14/19
05:54
Earnings
Nice raises FY19 EPS view to $5.15-$5.35 from $5.13-$5.33, consensus $5.26 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 26

    Nov

EMR

Emerson

$73.10

-0.47 (-0.64%)

05:52
11/14/19
11/14
05:52
11/14/19
05:52
Downgrade
Emerson rating change  »

HSBC downgrades Emerson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

NICE

Nice

$159.16

0.87 (0.55%)

05:51
11/14/19
11/14
05:51
11/14/19
05:51
Earnings
Nice reports Q3 EPS $1.30, consensus $1.28 »

Reports Q3 revenue $386M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 26

    Nov

MIME

Mimecast

$43.42

0.28 (0.65%)

05:50
11/14/19
11/14
05:50
11/14/19
05:50
Hot Stocks
Mimecast acquires DMARC Analyzer »

Mimecast announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PRGS

Progress Software

$41.49

-0.36 (-0.86%)

05:48
11/14/19
11/14
05:48
11/14/19
05:48
Hot Stocks
Progress Software appoints Katie Kulikoski as Chief People Officer »

Progress announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$52.81

-0.67 (-1.25%)

05:47
11/14/19
11/14
05:47
11/14/19
05:47
Earnings
Breaking Earnings news story on Weibo »

Weibo sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.